![](/img/cover-not-exists.png)
A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy
György Bodoky, Constanta Timcheva, David Robert Spigel, Phillip Joseph La Stella, Tudor Eliade Ciuleanu, G. Pover, N. C. TebbuttVolume:
30
Language:
english
Pages:
8
DOI:
10.1007/s10637-011-9687-4
Date:
June, 2012
File:
PDF, 640 KB
english, 2012